SuperworthMarker Therapeutics price to sales ratio MRKR
Market value divided by revenue over the last twelve months, since 2023.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 5.4×
- Aug 2026
- 4-year median
- 4.4×
- 4-year range
- 0.7× to 14.6×
- Peer median
- 0.9×
Marker Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Aug 2026, at 5.4×.
On the days it had one over the last 4 years, its median was 4.4×, from 0.7× in Mar 2023 to 14.6× in Jul 2024.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.4× | 4.7× | 8.2× |
| 2025 | 5.1× | 1.6× | 5.4× |
| 2024 | 5.8× | 3.6× | 14.6× |
| 2023 | 5.4× | 0.7× | 5.4× |
Against its peers
Companies in Drug Manufacturers - General nearest Marker Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| MRKRMarker Therapeutics | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| SPROSpero Therapeutics | 1.4× |
| LFVNLifevantage | 0.4× |
| Peer median | 0.9× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Marker Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.